Covered recipient · General Payments record
JONATHAN I SHEINBERG
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
General Payments · PY2018–2024
$3,415.47
- Reported across 197 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $340.73 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $168.54 | 7 |
| Amgen Inc. | $134.09 | 8 |
| Lilly USA, LLC | $22.91 | 1 |
| iRhythm Technologies, Inc. | $15.19 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $10.55 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705498 | CMS |
| Amgen Inc. | $14.06 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705500 | CMS |
| Amgen Inc. | $13.27 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705502 | CMS |
| Amgen Inc. | $25.56 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705504 | CMS |
| Amgen Inc. | $14.29 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705506 | CMS |
| Amgen Inc. | $15.56 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705508 | CMS |
| Amgen Inc. | $24.46 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705510 | CMS |
| Amgen Inc. | $16.34 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111705512 | CMS |
| iRhythm Technologies, Inc. | $15.19 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154046727 | CMS |
| Lilly USA, LLC | $22.91 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135073373 | CMS |
| Novo Nordisk Inc | $23.89 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097699990 | CMS |
| Novo Nordisk Inc | $23.51 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096855574 | CMS |
| Novo Nordisk Inc | $8.44 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096695395 | CMS |
| Novo Nordisk Inc | $23.13 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097825732 | CMS |
| Novo Nordisk Inc | $33.40 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097312606 | CMS |
| Novo Nordisk Inc | $33.40 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096608156 | CMS |
| Novo Nordisk Inc | $22.77 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097209196 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.